402 related articles for article (PubMed ID: 30422748)
21. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
22. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
23. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
24. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
25. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Gross G; Eshhar Z
Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
[TBL] [Abstract][Full Text] [Related]
27. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.
Xu XJ; Tang YM
Cancer Lett; 2014 Feb; 343(2):172-8. PubMed ID: 24141191
[TBL] [Abstract][Full Text] [Related]
28. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.
Cartellieri M; Bachmann M; Feldmann A; Bippes C; Stamova S; Wehner R; Temme A; Schmitz M
J Biomed Biotechnol; 2010; 2010():956304. PubMed ID: 20467460
[TBL] [Abstract][Full Text] [Related]
30. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Chmielewski M; Hombach AA; Abken H
Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
[TBL] [Abstract][Full Text] [Related]
31. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
[TBL] [Abstract][Full Text] [Related]
32. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
33. [CAR T-cell therapy: Balance of efficacy and safety].
Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
[TBL] [Abstract][Full Text] [Related]
34. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
35. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
36. Developing Infrastructure: Managing Patients With Cancer Undergoing CAR T-Cell Therapy
.
Halton E; Llerandi D; Diamonte C; Quintanilla H; Miale-Mayer D
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):35-40. PubMed ID: 28315556
[TBL] [Abstract][Full Text] [Related]
37. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
Wang J; Zhou P
Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
[TBL] [Abstract][Full Text] [Related]
38. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
39. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
Date V; Nair S
Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
[TBL] [Abstract][Full Text] [Related]
40. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
